MX2020009552A - Composiciones para prevenir y/o tratar melanoma. - Google Patents

Composiciones para prevenir y/o tratar melanoma.

Info

Publication number
MX2020009552A
MX2020009552A MX2020009552A MX2020009552A MX2020009552A MX 2020009552 A MX2020009552 A MX 2020009552A MX 2020009552 A MX2020009552 A MX 2020009552A MX 2020009552 A MX2020009552 A MX 2020009552A MX 2020009552 A MX2020009552 A MX 2020009552A
Authority
MX
Mexico
Prior art keywords
melanoma
methods
dapansutrile
treating melanoma
administration
Prior art date
Application number
MX2020009552A
Other languages
English (en)
Spanish (es)
Inventor
Carlo Marchetti
Charles A Dinarello
Original Assignee
Olatec Therapeutics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Olatec Therapeutics Llc filed Critical Olatec Therapeutics Llc
Publication of MX2020009552A publication Critical patent/MX2020009552A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2020009552A 2018-03-21 2019-03-18 Composiciones para prevenir y/o tratar melanoma. MX2020009552A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862645999P 2018-03-21 2018-03-21
PCT/US2019/022770 WO2019182981A1 (en) 2018-03-21 2019-03-18 Methods for treating melanoma

Publications (1)

Publication Number Publication Date
MX2020009552A true MX2020009552A (es) 2020-10-05

Family

ID=67987925

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020009552A MX2020009552A (es) 2018-03-21 2019-03-18 Composiciones para prevenir y/o tratar melanoma.

Country Status (7)

Country Link
US (1) US11857529B2 (https=)
EP (1) EP3768384B1 (https=)
JP (1) JP7229565B2 (https=)
CN (1) CN111867678B (https=)
CA (1) CA3094307A1 (https=)
MX (1) MX2020009552A (https=)
WO (1) WO2019182981A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12121565B2 (en) * 2019-09-13 2024-10-22 Duke University Methods of treatment of specific cancers with NLRP3 inhibitors and anti-PD1/PD-L1 antibodies
WO2021076444A1 (en) 2019-10-14 2021-04-22 Olatec Therapeutics Llc Methods for treating breast cancer
JP2024534040A (ja) * 2021-08-19 2024-09-18 オラテック セラピューティクス， インコーポレイティド パーキンソン病の治療方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2013006708A (es) * 2010-12-15 2013-09-13 Olatec Ind Llc Composicion de 3-metanosulfonilpropionitrilo para el tratamiento de la inflamacion y el dolor.
CA2875052C (en) * 2012-06-05 2020-07-14 Olatec Industries Llc Method for treating skin inflammatory diseases
CN104334165B (zh) * 2012-06-05 2017-09-05 欧拉泰克工业有限责任公司 用于治疗炎症和疼痛的药物组合物
SI3259253T1 (sl) * 2015-02-16 2020-07-31 The University Of Queensland Sulfonilsečnine in sorodne spojine ter njihova uporaba
US20160362489A1 (en) * 2015-04-28 2016-12-15 Bristol-Myers Squibb Company Treatment of PD-L1-Positive Melanoma Using an Anti-PD-1 Antibody
CA3021349A1 (en) * 2016-04-19 2017-10-26 Innate Tumor Immunity, Inc. Nlrp3 modulators
NL2017267B1 (en) * 2016-07-29 2018-02-01 Aduro Biotech Holdings Europe B V Anti-pd-1 antibodies
WO2018129231A1 (en) * 2017-01-06 2018-07-12 Olatec Therapeutics Llc Method for treating multiple sclerosis
EP3565540B1 (en) * 2017-01-06 2023-12-06 Olatec Therapeutics LLC A pharmaceutical composition for use in treating cardiovascular diseases
WO2018204764A1 (en) 2017-05-05 2018-11-08 Camp4 Therapeutics Corporation Identification and targeted modulation of gene signaling networks
WO2019152627A1 (en) * 2018-01-31 2019-08-08 Olatec Therapeutics Llc Method for preventing or treating alzheimer's disease

Also Published As

Publication number Publication date
US11857529B2 (en) 2024-01-02
CN111867678B (zh) 2023-04-28
CA3094307A1 (en) 2019-09-26
WO2019182981A1 (en) 2019-09-26
JP7229565B2 (ja) 2023-02-28
EP3768384A1 (en) 2021-01-27
US20200405681A1 (en) 2020-12-31
EP3768384A4 (en) 2021-11-17
JP2021518374A (ja) 2021-08-02
EP3768384B1 (en) 2025-06-25
CN111867678A (zh) 2020-10-30

Similar Documents

Publication Publication Date Title
MX2024000054A (es) Tratamiento de tumores positivos a gen 3 de activacion de linfocitos (lag-3).
AR126205A2 (es) Métodos de uso de linfocitos infiltrantes de tumor en melanoma doble refractario
MX382902B (es) Inhibidor de la vía noth en combinación con un agente inmunoterapéutico para usarse en el tratamiento de cáncer.
CR20220545A (es) ANTICUERPOS MONOCLONALES HUMANOS DIRIGIDOS CONTRA EL CORONAVIRUS 2 DEL SÍNDROME RESPIRATORIO AGUDO GRAVE (SARS-CoV-2)
PH12020500576A1 (en) Method of treating cancers with antagonistic anti-pd-1 antibodies
PH12019502076A1 (en) Methods for modulating an immune response
MX2020011653A (es) Métodos de tratamiento para el abuso de sustancias.
MX2022006073A (es) Metodos para utilizar anticuerpos anti-trem2.
SG10201811841UA (en) Methods of treating cancer using tigit inhibitors and anti-cancer agents
MX2020009552A (es) Composiciones para prevenir y/o tratar melanoma.
MY201811A (en) Method of reducing neutropenia
MX2022008868A (es) Tratamiento del cancer con tg02.
MX2019014274A (es) Metodo de tratamiento.
SG10201900072VA (en) A pharmaceutical combination and method for regulation of tumor microenvironment and immunotherapy
PH12019502316A1 (en) Combination cancer immunotheraphy with pentaaza macrocyclic ring complex
MX2021013354A (es) Metodos para tratar y/o prevenir queratosis actinica.
NZ748650A (en) Use of an anti-pd-1 antibody in combination with an anti-cd30 antibody in lymphoma treatment
MX386613B (es) El uso de un péptido timosina alfa y un inhibidor de pd-1 para el tratamiento de cáncer o una metástasis de este en un sujeto.
MX2017014198A (es) Desintoxicacion de los factores de virulencia microbiana en la cavidad oral.
MX394355B (es) Método de tratamiento de meduloblastoma con un inhibidor de ezh2.
ZA202201713B (en) Improved treatment using eyp001
JOP20210245A1 (ar) طرق لعلاج الداء النشواني من النوع خفيف السلسلة
AU2018282105A1 (en) Dosing of vibegron for treatment of overactive bladder
MX2019010101A (es) Composiciones y metodos para promover el crecimiento del cabello con inhibidores de mpc1.
MX2020002585A (es) Inhibidor de hdac combinado con un modulador del punto de control inmunitario para la terapia contra el cancer.